European Regulatory Round-Up: New Face At EMA, New Rules In France and Germany
Executive Summary
European Union
You may also be interested in...
Zelboraf And Yervoy Benefit From Secret Discounts To Pass NICE Barrier
NICE has recommended Roche’s Zelboraf and BMS’ Yervoy, as expected based partly on undeniable life extension capabilities, but also on secret price discounts offered by both manufacturers.
Bristol Will Leap 'Over Its Patent Cliff,' In 2013, Sigal Tells Investors
With a dozen approvals in the past eight years, the company believes it has "eradicated" its patent cliff and is looking at a significant growth cycle.
Mediator Scandal Provokes Flurry of French Health Reforms But Impact Is Hard To Gauge Until The Dust Settles
France is facing various reforms to its health care system as a direct result of the scandal involving Servier’s diabetes drug Mediator (benfluorex), which may have caused up to 500 deaths.